



## **ASH 2022 abstracts: What's hot in GvHD?**

To help navigate the exciting content being presented at the 64th ASH Annual Meeting & Exposition, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD, in 3 categories: GvHD prophylaxis and early phase trials; novel therapies; and clinical biomarkers and risk stratification.



**Click**  
the abstracts  
to view

## GvHD prophylaxis and early phase trials

<b>LBA-4</b>	<a href="#"><u>Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703</u></a>
<b>111</b>	<a href="#"><u>Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial</u></a>
<b>572</b>	<a href="#"><u>Ruxolitinib in Pediatric Patients with Treatment-Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study</u></a>
<b>573</b>	<a href="#"><u>Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial</u></a>
<b>574</b>	<a href="#"><u>Addition of Ruxolitinib to Corticosteroids As First-Line Therapy for High-Risk Acute Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation</u></a>
<b>770</b>	<a href="#"><u>Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy</u></a>
<b>771</b>	<a href="#"><u>Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309</u></a>
<b>772</b>	<a href="#"><u>Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis</u></a>
<b>773</b>	<a href="#"><u>Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant</u></a>

## Novel therapies

<b>112</b>	<a href="#"><u>Pooled Fecal Allogeneic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France</u></a>
<b>769</b>	<a href="#"><u>Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide</u></a>
<b>774</b>	<a href="#"><u>RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation</u></a>

## Risk stratification

<b>113</b>	<a href="#"><u>Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis</u></a>
------------	--





Follow us on Twitter to keep up to date  
with the latest from the 64th ASH Annual  
Meeting & Exposition!

**@gvhd\_hub**  
**#ASH22**  
**gvhdhub.com**